Opinion
Video
Panelists discuss the clinical findings of elacestrant, an oral selective estrogen receptor degrader (SERD), for the treatment of ER+/HER2– metastatic breast cancer.
Video content above is prompted by the following:
Dr. Bardia to Dr. Gradishar: Please mention highlights of recent elacestrant studies: